ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show sustained anti-tumor activity of AP26113 in patients with anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with active brain metastases. The updated Phase 1/2 trial now contains more mature data of AP26113, including increasing depth and durability of response in ALK+ NSCLC patients, as well as additional safety data. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its eekly performance is -3.05%. On last trading day company shares ended up $5.40. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -7.43%.
Larry Ellison was the main draw for tens of thousands of technology professionals at Oracle Corporation (NYSE:ORCL)’s annual conference in San Francisco on Tuesday, where he joked about losing his name after relinquishing his role as the company’s CEO. Oracle Corporation (NYSE:ORCL) shares decreased -0.42% in last trading session and ended the day at $38.28. ORCL Gross Margin is 81.10% and its return on assets is 12.10%. Oracle Corporation (NYSE:ORCL) quarterly performance is -5.83%.
Zacks upgraded shares of JGWPT Holdings (NYSE:JGW) from a neutral rating to an outperform rating in a research report sent to investors on Wednesday morning. The firm currently has $14.10 price target on the stock. On 30 September, JGWPT Holdings Inc. (NYSE:JGW) shares moved up 1.14% and was closed at $12.39. JGW EPS growth in last 5 year was 0.00%. JGWPT Holdings Inc. (NYSE:JGW) year to date (YTD) performance is -28.75%.
Argan, Inc. (NYSE:AGX) announced that Arthur Trudel will retire as Chief Financial Officer and Senior Vice President in January 2015. Cynthia Flanders, a member of Argan’s board of directors, will succeed Trudel as CFO. Trudel has been Argan’s CFO since joining the Company in April 2003. Argan, Inc. (NYSE:AGX) ended the last trading day at $33.38. Company weekly volatility is calculated as 3.57% and price to cash ratio as 1.40. Argan, Inc. (NYSE:AGX) showed a weekly performance of -4.33%.
Zacks reissued their neutral rating on shares of The Allstate (NYSE:ALL) in a research report sent to investors on Tuesday morning. They currently have a $64.00 price target on the stock. The Allstate Corporation (NYSE:ALL) shares moved up 0.13% in last trading session and ended the day at $61.37. ALL return on assets is 1.90%. The Allstate Corporation (NYSE:ALL) quarterly performance is 4.28%.